ASX:TLXBiotechs
Early ProstACT Phase 3 Safety Data Could Be A Game Changer For Telix (ASX:TLX)
Telix Pharmaceuticals recently reported Part 1 data from its ProstACT Global Phase 3 trial in metastatic castration-resistant prostate cancer, showing TLX591-Tx had an acceptable safety and tolerability profile with no new safety signals when combined with standard-of-care therapies.
The findings underline a potentially differentiated safety profile versus existing PSMA-targeted radioligand therapies, with lower kidney and salivary gland exposure that may be clinically meaningful for...